Article Sidebar
Views PDF: 207
RELATIONSHIP BETWEEN FECAL CALPROTECIN CONTENTS AND SOME CLINICAL CHARACTERISTICS, CHEMICAL INTRODUCTION IN CONTRAINDICATION PATIENTS
Main Article Content
Abstract
The objective was to determine the relationship between calprotectin levels and clinical and laboratory characteristics in patients with inflammatory bowel disease. The study was conducted on 34 patients with confirmed inflammatory bowel disease (IBD) and 20 patients with irritable bowel disease. Cross-sectional descriptive research method. Calprotectin quantitative research technique by direct chemiluminescence immunoassay on Laison XL machine of Diansorin Germany. The study results showed that there was a statistically significant relationship between calprotectin concentration in stool with disease activity level of IBD, number of bowel movements and blood stool level with (p < 0.001). There is a relationship between calprotectin levels and the extent of colonic lesions on colonoscopy in IBD patients. Calprotectin test is valuable in diagnosing IBD with cut-off point 55.25mg/kg, sensitivity 92.3%, specificity 75%. The area under the ROC curve was 0.911, with p < 0.01. The mean Calprotectin concentration in the group with abnormal CRP concentrations (≥ 5mg/L) was 175.8 ± 132.9 (mg/kg), much higher than the mean Calprotectin concentration in the group with average CRP concentrations. normal (57.19 ± 32.3 mg/kg). The difference between the 2 groups was statistically significant with p < 0.01. Conclusion: Concentration of calprotectin in stool is related to disease severity, number of bowel movements and colonic lesions on colonoscopy. Calprotectin test is valuable in diagnosing IBD with a sensitivity of 92.3%, a specificity of 75% with a cut-off point of 55.25mg/kg
Article Details
Keywords
Inflammatory bowel disease, Calprotectin, clinical relevance, CRP, endoscopy
References
2. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. “ACG Clinical Guideline: Management of Crohn’s Disease in Adults” [published correction appears in Am J Gastroenterol. 2018 Jul;113(7):1101]. Am J Gastroenterol. 2018;113(4):481-517. Doi:10. 1038/ajg.2018.27.
3. Lin W et al. (2015), "Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients", World journal of gastroenterology. 21(48), pp. 13566.
4. Lobaton T et al. (2013), "A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease", J Crohns Colitis. 7(12), pp. e641-51.
5. Samant H et al. (2015), "Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease", Indian Journal of Gastroenterology. 34(6), pp. 431-435.
6. Schoepfer A. M et al. (2013), "Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes", Inflamm Bowel Dis. 19(2), pp. 332-41.
7. Rodgers A. D & Cummins A. G (2007), "CRP correlates with clinical score in ulcerative colitis but not in Crohn’s disease", Digestive diseases and sciences. 52(9), pp. 2063-2068.
8. Karoui S et al. (2011), "Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis", Digestive diseases and sciences. 56(6), pp. 1801-1805.